Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2021 - 2025)

ARS Pharmaceuticals' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $327.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 6.69% year-over-year to $327.7 million; the TTM value through Dec 2025 reached $1.3 billion, up 31.71%, while the annual FY2025 figure was $327.7 million, 6.69% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $327.7 million at ARS Pharmaceuticals, down from $372.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $382.2 million in Q1 2021 and bottomed at $61.4 million in Q4 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $287.7 million (2022), against an average of $284.7 million.
  • The largest YoY upside for Liabilities and Shareholders Equity was 358.02% in 2022 against a maximum downside of 23.12% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $61.4 million in 2021, then skyrocketed by 358.02% to $281.4 million in 2022, then decreased by 17.14% to $233.2 million in 2023, then surged by 50.59% to $351.2 million in 2024, then decreased by 6.69% to $327.7 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Liabilities and Shareholders Equity are $327.7 million (Q4 2025), $372.8 million (Q3 2025), and $313.5 million (Q2 2025).